Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors. The Food and Drug Administration (FDA) approval of ...

The product is administered over a period of 3 to 5 minutes into the subcutaneous tissue of the ... option used in many indications across tumor types,” said Adam Lenkowsky, executive vice ...

injection for subcutaneous use. This combination product of nivolumab co-formulated with recombinant human hyaluronidase (rHuPH20) is approved for most previously approved adult solid tumor Opdivo ...

injection for subcutaneous use for most previously approved adult, solid tumor Opdivo (nivolumab) indications. Opdivo Qvantig is a combination product of nivolumab coformulated with recombinant ...